ReviewEuropean journal of nuclear medicine and molecular imaging2025
Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy.
Review in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026Review
- Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Frontiers in oncology · 2026Review
- From Semantic Modeling to Precision Radiotherapy: An AI Framework Linking Radiobiology, Oncology, and Public Health Integration.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing interest and investments in targeted radionuclide therapy (TRT) have expanded research efforts across preclinical and clinical domains. Researchers from diverse fields, including nuclear medicine, radiochemistry, radiopharmacy, radiotherapy, biology, and physics, are increasingly focusing on TRT. Despite this, a lack of standardization in preclinical radiobiological studies hinders the evaluation and comparison of therapeutic radiopharmaceuticals across laboratories. Recognizing this, participants at the second International Workshop on Radiobiology of Molecular Radiotherapy, held in London, UK, in March 2023, emphasized the need for a consensus on nomenclature and standardized reporting guidelines in this field. The recommendations outlined here aim to address this gap by promoting consistent reporting. By adopting these standards, we hope to enhance the reproducibility, inter-laboratory comparability and visibility of preclinical TRT research, ultimately accelerating progress and amplifying its impact on the field and clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.